Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05510115 · ClinicalTrials.gov registry record · Phase 2
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
A Phase 2 study of Polycystic Kidney, Autosomal Dominant, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05510115 is a Phase 2 study of Polycystic Kidney, Autosomal Dominant that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 50 participants, below the 65-participant average among 4 other Polycystic Kidney, Autosomal Dominant trials with a reported enrollment target (23% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05510115, a Phase 2 study of Polycystic Kidney, Autosomal Dominant, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigator proposes a pilot randomized clinical trial to determine the safety and tolerability of empagliflozin in ADPKD patients. To achieve this, the investigator will conduct a 12-month parallel-group, randomized, double-blind, placebo-controlled trial in 50 ADPKD patients with an eGFR 30-90 mL/min/1.73m2.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Empagliflozin
Study Locations (1)
Colorado
- University of Coloardo Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-11-18 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05510115
The ClinicalTrials.gov registry entry for NCT05510115 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 4 other Polycystic Kidney, Autosomal Dominant trials with a reported enrollment target (23% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Polycystic Kidney, Autosomal Dominant appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05510115 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT05510115 about?
NCT05510115 is a clinical study titled "Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease". The investigator proposes a pilot randomized clinical trial to determine the safety and tolerability of empagliflozin in ADPKD patients. To achieve this, the investigator will conduct a 12-month parallel-group, randomized, double-blind, placebo-controlled trial in 50 ADPKD patients with an eGFR 30-9...
What is the current status of trial NCT05510115?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2022-11-18. Estimated completion is 2026-03-31.
What conditions does trial NCT05510115 study?
This clinical trial studies the following conditions: Polycystic Kidney, Autosomal Dominant.
What interventions are being tested in trial NCT05510115?
The interventions under investigation include: Placebo (DRUG), Empagliflozin (DRUG).
Who is sponsoring clinical trial NCT05510115?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05510115 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polycystic Kidney, Autosomal Dominant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
COMPLETED · Phase 2
-
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
COMPLETED · NA
-
Effect of Venglustat in Patients With Renal Impairment
COMPLETED · Phase 1
-
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.